<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2013-0-3-52-57</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-173</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОПЫТ ЛЕЧЕБНЫХ УЧРЕЖДЕНИЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIENCE OF HEALTHCARE FACILITIES</subject></subj-group></article-categories><title-group><article-title>ВОЗМОЖНОСТИ ЛЕЧЕНИЯ БОЛЬНЫХ РАКОМ ЖЕЛУДКА С МЕТАСТАЗАМИ В КОСТИ СКЕЛЕТА</article-title><trans-title-group xml:lang="en"><trans-title>THE POSSIBILITY OF TREATING PATIENTS WITH GASTRIC CANCER WITH METASTASES TO THE BONES OF THE SKELETON</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Расулова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rasulova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Расулова Нигора Валиевна - заведующий отделением радиоизотопной диагностической  лаборатории.</p><p>100115, Ташкент, ул.Фархадская, д. 10, тел. (+99871) 277-26-51, e-mail: niga_r@mail.ru </p></bio><bio xml:lang="en"><p>Department of radioisotope diagnostic laboratory, Tashkent </p></bio><email xlink:type="simple">niga_r@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Арыбжанов</surname><given-names>Д. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Arybzhanov</surname><given-names>D. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Арыбжанов Дауранбек Турсункулович - заведующий отделением химиотерапии и эндоваскулярной онкологии.</p><p>160021, Шымкент, ул. А. Байтурсынова, б/н, тел. 8 (7252) 22-19-54, e-mail: davran_a@mail.ru</p></bio><bio xml:lang="en"><p>Department of chemotherapy and endovascular oncology, Shymkent</p></bio><email xlink:type="simple">davran_a@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Джалалов</surname><given-names>Ф. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Dzhalalov</surname><given-names>F. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Джалалов Фаррух  Зиявутдинович - врач отделения интервенционной радиологии.</p><p>100115, Ташкент, ул.Фархадская, д. 10, тел. (+99897) 7051733, е-mail: dj_fa@mail.ru</p></bio><bio xml:lang="en"/><email xlink:type="simple">dj_fa@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ким</surname><given-names>Кьенг Хван</given-names></name><name name-style="western" xml:lang="en"><surname>Kim</surname><given-names>Kyeong Hwan</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кьенг Хван Ким - главный директор спинального центра, отделение ортопедической хирургии.</p><p>472-701, Hunday General Hospital 663, Janghyen-Ri,Jinjeip-Eup, South Korea, тел. 8 (210) 378-66-576, e-mail: ponticuli@naver.com</p></bio><bio xml:lang="en"><p>Department of Orthopaedics, Namyangzhu</p></bio><email xlink:type="simple">ponticuli@naver.com</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Республиканский Специализированный Центр Хирургии  имени академика  В. Вахидова</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>Acad. V. Vakhidov’s Republican Specialized Center of Surgery</institution><country>Uzbekistan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Южно-Казахстанский областной онкологический диспансер</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>South Kazakhstan Regional Oncology Center</institution><country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Республиканский Научный Центр Экстренной медицинской помощи</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>National Research Centre for Emergency Medicine</institution><country>Uzbekistan</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Госпиталь Хундай</institution><country>Северная Корея</country></aff><aff xml:lang="en"><institution>Hospital Hyundai</institution><country>Korea, Democratic People's Republic of</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>02</day><month>02</month><year>2017</year></pub-date><volume>0</volume><issue>3</issue><fpage>52</fpage><lpage>57</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Расулова Н.В., Арыбжанов Д.Т., Джалалов Ф.З., Ким К.Х., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Расулова Н.В., Арыбжанов Д.Т., Джалалов Ф.З., Ким К.Х.</copyright-holder><copyright-holder xml:lang="en">Rasulova N.V., Arybzhanov D.T., Dzhalalov F.Z., Kim K.H.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/173">https://www.surgonco.ru/jour/article/view/173</self-uri><abstract><p>Анализированы результаты лечения  14 больных  раком  желудка  с метастазами в кости скелета,  которым  проводилась стабилизация метастатических позвонков путем вертебропластики, системная радионуклидная терапия Самарием – 153 оксабифором и внутривенные инфузии Золендроновой кислоты 4 мг 1 раз в 28 дней. При применении данной методики отмечено снижение боли вследствие стабилизации позвонков, наступившее в первые 12 часов после вертебропластики (ср. значение 4,8±1,2 часа: от 30 минут до 12 часов), среднее значение интенсивности боли  снизилось до 4,5±0,6 (от 2 до 6). </p><p>После  терапии  костных  метастазов  Самарием-153  оксабифором  интенсивность болевого  синдрома  снизилась  через  3,9±0,3  дней  (от  2  до  6)  и  достигла  уровня 0,9±0,5(от 0 до 2). Значение по болевой шкале до и после лечения  статистически достоверно отличалось и составило P&lt; 0,0001.</p><p>Таким образом, комбинация вертебропластики, радионуклидной терапии самарием-153 оксабифором и системной терапии бисфосфонатами (Золендроновая кислота) у больных   раком  желудка  с метастазами в кости позволяет проводить лечение при наличии  или угрозе переломов позвонков, что дает возможность расширить показания для паллиативной радионуклидной терапии и повысить  эффективность лечения тяжелой категории больных с множественными метастазами в кости и болевым синдромом. Предложенный подход  позволяет быстро  достичь  стойкого  и выраженного снижения интенсивности болевого синдрома, существенно снизить потребность в анальгетиках.</p></abstract><trans-abstract xml:lang="en"><p>The results of treatment of 14 patients with gastric cancer with metastases to the bones of the skeleton  were analized, which was conducted by the stabilization of metastatic spine vertebroplasty, systemic  radionuclide therapy with  samarium-153 oksabifor and  intravenous infusion  by Zolendronic  acid 4 mg 1 time in 28 days. When applying this method decreased by stabilizing vertebral  pain occurred in the first 12 hours after vertebroplasty (cf. value 4.8±1,2 hours, from 30 minutes to 12 hours), the average pain intensity decreased to 4.5 ±0,6 (from 2 to 6). After the treatment of bone  metastases with samarium-153 oksa bifor,  pain intensity  decreased by 3,9 ± 0,3 days (range from 2 to 6) and reached the level of 0,9 ± 0,5 (from 0 to 2). Value pain scores before and after treatment was significantly different, and was P &lt;0,0001. </p><p>Thus,  the  combination of  vertebroplasty, radionuclide therapy  with  samarium-153 oksabifor and  systemic  therapy with bisphosphonates (Zolendronic acid)  in patients with gastric  cancer  with bone  metastases can be treated in the  presence or threat of vertebral fractures, which gives an opportunity to expand the  indications for palliative radionuclide therapy and improve efficiency treatment of severe category of patients with multiple bone metastases and pain. The proposed approach allows us to quickly achieve durable  and pronounced reduction in pain intensity, significantly  reduce the need for analgesics.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>системная радионуклидная терапия</kwd><kwd>вертебропластика</kwd><kwd>костные метастазы</kwd><kwd>перелом позвоночника</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic  radionuclide  therapy</kwd><kwd>vertebroplasty</kwd><kwd>bone  metastases</kwd><kwd>spinal  Fracture</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Barbanti Brodano G., Cappuccio M., et al. Vertebroplasty in the treatment of vertebral metastases: clinical cases and review of the literature // European Review for Medical and Pharmacological Sciences. – 2007. – Vol. 11. – P. 91-100.</mixed-citation><mixed-citation xml:lang="en">Barbanti Brodano G., Cappuccio M., et al. Vertebroplasty in the treatment of vertebral metastases: clinical cases and review of the literature // European Review for Medical and Pharmacological Sciences. – 2007. – Vol. 11. – P. 91-100.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bodei Lisa, Lam Marnix, Chiesa Carlo, et al. EANM procedure guideline for treatment of refractory metastatic bone pain // Eur J Nucl Med Mol Imaging. 2008.</mixed-citation><mixed-citation xml:lang="en">Bodei Lisa, Lam Marnix, Chiesa Carlo, et al. EANM procedure guideline for treatment of refractory metastatic bone pain // Eur J Nucl Med Mol Imaging. 2008.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Boland PJ, Lane JM, Sundaresan N. Metastatic disease of the spine // Clin Orthop Relat Res. – 1982. – Vol. 169. – P. 95-102.</mixed-citation><mixed-citation xml:lang="en">Boland PJ, Lane JM, Sundaresan N. Metastatic disease of the spine // Clin Orthop Relat Res. – 1982. – Vol. 169. – P. 95-102.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bunting R., Lamont-Havers, W., Schweon, D., Kliman, A., Pathologic fracture risk in rehabilitation of patients with bony metastases // Clin Orthop. – 1985. – Vol. 192. – P. 222–227.</mixed-citation><mixed-citation xml:lang="en">Bunting R., Lamont-Havers, W., Schweon, D., Kliman, A., Pathologic fracture risk in rehabilitation of patients with bony metastases // Clin Orthop. – 1985. – Vol. 192. – P. 222–227.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies // Cancer Treat Rev. – 2001. – Vol. 27. – P. 165–176.</mixed-citation><mixed-citation xml:lang="en">Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies // Cancer Treat Rev. – 2001. – Vol. 27. – P. 165–176.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Falkmer U., Jarhult J., Wersall P. et al. A systematic overview of radiation therapy effects in skeletal metastases // Acta Oncol. – 2003. – Vol. 42. – P. 620–633.</mixed-citation><mixed-citation xml:lang="en">Falkmer U., Jarhult J., Wersall P. et al. A systematic overview of radiation therapy effects in skeletal metastases // Acta Oncol. – 2003. – Vol. 42. – P. 620–633.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Harrington K.D. Metastatic disease of the spine // J Bone Joint Surg Am. – 1986. – Vol. 68. – P. 1110-1115.</mixed-citation><mixed-citation xml:lang="en">Harrington K.D. Metastatic disease of the spine // J Bone Joint Surg Am. – 1986. – Vol. 68. – P. 1110-1115.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Houfu Deng et all. Radiopharmaceutical (Sm-153-EDTMP) therapy of skeletal metastases:clinical application in 350 patients // The Journal of Radiology. August 2002, www.jradiology.org</mixed-citation><mixed-citation xml:lang="en">Houfu Deng et all. Radiopharmaceutical (Sm-153-EDTMP) therapy of skeletal metastases:clinical application in 350 patients // The Journal of Radiology. August 2002, www.jradiology.org</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jensen A. et al. Incidence of bone metastases and skeletal-related events in breast cancer patients: A populationbased cohort study in Denmark // BMC Cancer. – 2011. – Vol. 11. – P. 29.</mixed-citation><mixed-citation xml:lang="en">Jensen A. et al. Incidence of bone metastases and skeletal-related events in breast cancer patients: A populationbased cohort study in Denmark // BMC Cancer. – 2011. – Vol. 11. – P. 29.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kanis J.A. Bone and cancer: pathophysiology and treatment of metastases // Bone. – 1995. – Vol. 17. – P. 101–105.</mixed-citation><mixed-citation xml:lang="en">Kanis J.A. Bone and cancer: pathophysiology and treatment of metastases // Bone. – 1995. – Vol. 17. – P. 101–105.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kosteva J., Langer C. Skeletal metastases of non-small cell lung cancer:advances in diagnosis and treatment. In Carbone D (ed): Lung Cancer Principles and Practices. Philadelphia, PA: Lippincott Williams and Williams, 2003. – P. 1–14.</mixed-citation><mixed-citation xml:lang="en">Kosteva J., Langer C. Skeletal metastases of non-small cell lung cancer:advances in diagnosis and treatment. In Carbone D (ed): Lung Cancer Principles and Practices. Philadelphia, PA: Lippincott Williams and Williams, 2003. – P. 1–14.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Langdon J, Bernard J, Molloy S. Prophylactic stabilization of vertebral body metastasis at risk of imminent fracture using balloon kyphoplasty // Spine (Phila Pa 1976). 2009. – Vol. 34. – P. 469-472.</mixed-citation><mixed-citation xml:lang="en">Langdon J, Bernard J, Molloy S. Prophylactic stabilization of vertebral body metastasis at risk of imminent fracture using balloon kyphoplasty // Spine (Phila Pa 1976). 2009. – Vol. 34. – P. 469-472.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mendel E., Bourekas E., Gerszten P. et al. Percutaneous techniques in the treatment of spine tumors: what are the diagnostic and therapeutic indications and outcomes? // Spine (Phila Pa 1976). 2009. – Vol. 34. – P. 93-100.</mixed-citation><mixed-citation xml:lang="en">Mendel E., Bourekas E., Gerszten P. et al. Percutaneous techniques in the treatment of spine tumors: what are the diagnostic and therapeutic indications and outcomes? // Spine (Phila Pa 1976). 2009. – Vol. 34. – P. 93-100.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sybil J. Biermann, Ginger E. Holt, et al. Metastatic Bone Disease: Diagnosis, Evaluation, and Treatment // J Bone Joint Surg Am. – 2009. –Vol. 91. –P. 1518-1530.</mixed-citation><mixed-citation xml:lang="en">Sybil J. Biermann, Ginger E. Holt, et al. Metastatic Bone Disease: Diagnosis, Evaluation, and Treatment // J Bone Joint Surg Am. – 2009. –Vol. 91. –P. 1518-1530.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ryken T.C., Eichholz K.M., Gerszten P.C., Welch W.C., Gokaslan Z.L., Resnick D.K. Evidence-based reviewof the surgical management of vertebral column metastatic disease Neurosurg Focus. – 2003. – Vol. 15(5). – P. 11.</mixed-citation><mixed-citation xml:lang="en">Ryken T.C., Eichholz K.M., Gerszten P.C., Welch W.C., Gokaslan Z.L., Resnick D.K. Evidence-based reviewof the surgical management of vertebral column metastatic disease Neurosurg Focus. – 2003. – Vol. 15(5). – P. 11.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
